产品
编 号：F762624
分子式：C29H23Cl2NO4
分子量：520.4
分子式：C29H23Cl2NO4
分子量：520.4
产品类型
规格
价格
是否有货
结构图
CAS No: 3004676-77-8
产品详情
生物活性：
ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH).
体内研究：
ZLY28 (oral; 20 mg/kg) 通过调节 NASH 小鼠模型中的脂质代谢、炎症、氧化应激和纤维化等多种发病机制显着缓解脂肪肝。Animal Model:8 weeks old male C57BL/6 mice
Dosage:20 mg/kg
Administration:Oral administration
Result:Mainly distributed in the ileum with an ileum/plasma ratio of 104.1.Significantly alleviated hepatic steatosis, lobular inflammation and ballooning.Improved hepatic lipid homeostasis by inhibiting lipogenesis and promoting lipolysis.Downregulated the gene expression levels.Exhibited an acceptable safety profile with no acute toxicity.
体外研究：
ZLY28 具有合适的肝微粒体稳定性，对 FXR（EC50 = 143 nM）和 FABP1（IC50 = 2.7 μM）具有高靶向选择性.
ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH).
体内研究：
ZLY28 (oral; 20 mg/kg) 通过调节 NASH 小鼠模型中的脂质代谢、炎症、氧化应激和纤维化等多种发病机制显着缓解脂肪肝。Animal Model:8 weeks old male C57BL/6 mice
Dosage:20 mg/kg
Administration:Oral administration
Result:Mainly distributed in the ileum with an ileum/plasma ratio of 104.1.Significantly alleviated hepatic steatosis, lobular inflammation and ballooning.Improved hepatic lipid homeostasis by inhibiting lipogenesis and promoting lipolysis.Downregulated the gene expression levels.Exhibited an acceptable safety profile with no acute toxicity.
体外研究：
ZLY28 具有合适的肝微粒体稳定性，对 FXR（EC50 = 143 nM）和 FABP1（IC50 = 2.7 μM）具有高靶向选择性.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备